Name: $6.99 | Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen | Pill Pals
Brand: ScieGen
SKU: 50228-0124-10-30p
Price: 6.99 USD
Availability: InStock

Description

Clopidogrel 75 mg Tablets is available by prescription only. Go ahead and place your purchase. After making payment, we will ensure that a valid prescription is received from your prescriber.

Drug Label Highlights

Source: This information is taken from the official DailyMed drug label page when available. It is provided for educational purposes and is not a substitute for pharmacist counseling, prescriber instructions, or the full official labeling.

These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.

CLOPIDOGREL tablets, for oral use

Initial U.S. Approval: 1997

WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE

See full prescribing information for complete boxed warning.

Effectiveness of clopidogrel depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (

5.1,

12.3)

Tests are available to identify patients who are CYP2C19 poor metabolizers. (

12.5)

Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers. (

5.1)

Indications And Usage

Clopidogrel is a P2Y

12platelet inhibitor indicated for:

Acute coronary syndrome

For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. (

1.1)

For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. (

1.1)

Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. (

1.2)

Dosage And Administration

Acute coronary syndrome (

2.1)

Initiate clopidogrel with a single 300-mg oral loading dose and then continue at 75 mg once daily.

Initiate clopidogrel without a loading dose will delay establishment of an antiplatelet effect by several days.

Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose (

2.2)

Dosage Forms And Strengths

Tablets: 75 mg, 300 mg (

Contraindications

Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (

4.1)

Hypersensitivity to clopidogrel or any component of the product (

4.2)

Warnings And Precautions

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (5.1)
Bleeding: Clopidogrel increases risk of bleeding. (5.2)
Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. (5.3)
Thrombotic thrombocytopenic purpura (TTP) has been reported. (5.4)
Cross-reactivity among thienopyridines has been reported. (5.5)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (5.1)
Bleeding: Clopidogrel increases risk of bleeding. (5.2)
Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. (5.3)
Thrombotic thrombocytopenic purpura (TTP) has been reported. (5.4)
Cross-reactivity among thienopyridines has been reported. (5.5)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole.

(5.1)

Bleeding: Clopidogrel increases risk of bleeding.

(5.2)

Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding.

(5.3)

Thrombotic thrombocytopenic purpura (TTP) has been reported.

(5.4)

Cross-reactivity among thienopyridines has been reported.

(5.5)

Adverse Reactions

Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. (

6.1)

To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals Inc at 1-855-724-3436or FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch.

Drug Interactions

CYP2C19 inducers: Increases levels of clopidogrel active metabolite and increases platelet inhibition. (

7.1)

Opioids: Decreased exposure to clopidogrel. Consider use of parenteral antiplatelet agent.

(7.3)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding.

(7.4,

7.5,

7.6)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (7.7)

Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations. (7.8)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2023

View Full DailyMed Label View DailyMed PDF

DailyMed highlights last updated: 2026-06-24 22:37:02

Additional information

Size/Count	30 Count
Dose/Strength	75 mg
Form	Tablet

Medication Guide

Official DailyMed Drug Label Information

This product has a DailyMed drug label PDF from the National Library of Medicine.

View / Download PDF View on DailyMed

Source: DailyMed, National Library of Medicine
DailyMed Label: CLOPIDOGREL BISULFATE TABLET, FILM COATED [SCIEGEN PHARMACEUTICALS INC]
Matched NDC: 50228-124-10
Published Date: Oct 13, 2023

Medication Summary

Medication Summary: This section summarizes DailyMed drug label information to make the label easier to understand. It is not a substitute for the official label, pharmacist counseling, prescriber instructions, or medical advice.

Overview

Clopidogrel tablets are a P2Y12 platelet inhibitor used to help reduce the rate of heart attack and stroke in certain patients with acute coronary syndrome, recent heart attack, recent stroke, or established peripheral arterial disease. For some acute coronary syndrome patients, the tablet is given with aspirin.

The label says clopidogrel works by blocking platelet activation and aggregation after it is converted to an active metabolite in the body. It also warns that the medicine may be less effective in people with two loss-of-function CYP2C19 alleles, and that tests are available to identify CYP2C19 poor metabolizers.

Bleeding is the most commonly reported adverse reaction. The label also warns about serious bleeding, thrombotic thrombocytopenic purpura (TTP), and reduced effect when used with omeprazole or esomeprazole. Stopping clopidogrel too soon can raise the risk of cardiovascular events.

Storage Information

store hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective. STORAGE AND HANDLING Clopidogrel tablets, USP 75 mg are available as pink colored, round shaped, biconvex, film coated tablets de-bossed on one side with SG and 124 on other side. Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature]. store clopidogrel tablets? Store clopidogrel tablets at 59°F to 86°F (15°C to 30°C).

Key Counseling Points

Take clopidogrel exactly as prescribed.
Clopidogrel may be taken with or without food.
Tell your healthcare provider about all medicines you take, including omeprazole or esomeprazole.
Watch for signs of bleeding, since clopidogrel can increase bleeding risk.
Do not stop clopidogrel without medical direction, because stopping can increase the risk of cardiovascular events.
Let your healthcare provider know if you have a history of bleeding or an active bleeding condition.
Tell your healthcare provider if you have had a reaction to clopidogrel or other thienopyridines.
Seek urgent attention for symptoms listed in the label for TTP, such as low platelets, anemia, neurologic findings, kidney problems, or fever.
Tell your healthcare provider if you are scheduled for surgery, because the label says clopidogrel may need to be interrupted 5 days before surgery with a major risk of bleeding.

Helpful Patient Education

Clopidogrel tablets are a prescription antiplatelet medicine used to reduce the risk of heart attack and stroke in certain patients with acute coronary syndrome, recent heart attack, recent stroke, or established peripheral arterial disease. The label also describes important safety information, including bleeding risk, possible reduced effect in CYP2C19 poor metabolizers, and drug interactions with medicines such as omeprazole and esomeprazole.

This product page summarizes DailyMed label information in plain language for educational use. It includes key uses, dosing concepts, warnings, adverse reactions, and handling information for clopidogrel bisulfate tablets, film coated.

Medication Summary last generated: 2026-07-17 02:59:16

Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen may require patient-specific counseling based on your prescription, directions, allergies, medical history, and other medications.

This Medication Guide section is provided for general educational purposes only. It does not replace the official medication guide, patient information leaflet, counseling from your pharmacist, or medical advice from your prescriber.

Please read all information provided with your prescription. Contact Pill Pals Pharmacy or your prescriber with questions before using this medication.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen

Description